PODD enters its Q1 2026 earnings report — due today — with the most bullish options positioning of the past year and a stock that has lost more than a quarter of its value in a month.
The options market has made a decisive shift toward calls. The put/call ratio has collapsed to 0.71, more than two standard deviations below its 20-day average of 1.01 and the lowest reading in the past 52 weeks. That is a striking rotation into call exposure — investors are leaning on upside protection rather than downside hedges, even as the stock has fallen 26% over the past month to $151.28. The contrast is sharp: the price has been crushed, but options traders are betting on a rebound from the lows. Short interest has eased alongside the selloff, falling nearly 4% over the week to 3.75% of the free float — a moderate level that carries no meaningful squeeze pressure. Borrow remains essentially free at 0.49%, and lending availability is extremely loose, meaning the short-selling infrastructure for a bigger bear thesis is in place but not yet being used.
The Street has been in near-unanimous retreat on price targets, yet most firms are holding their Buy ratings — a pattern that captures the bull-bear tension precisely. Goldman Sachs trimmed to $277 in April while maintaining Buy. Truist cut to $315, also keeping Buy. BTIG lowered to $260 on the day of the earnings release itself, still at Buy. The notable exception is Citigroup, which downgraded to Neutral and cut to $230 in early April, and Rothschild, which moved to Neutral from Buy with a $220 target later in the month. The mean consensus target across the Street sits near $277 — still 83% above where the stock is trading. Bulls point to Q4 2025 revenues of $784 million, up 31% year-over-year, record new customer starts, and an expanding manufacturing footprint in Malaysia and Costa Rica. Bears flag a roughly 50% decline in drug delivery revenues, intensifying competition in the insulin pump market, and the risk that growth projections for the US Omnipod system — estimated at 20–22% — fall short of what the valuation demands. EV/EBITDA has compressed to 13.9x, down from 14.6x thirty days ago, reflecting the re-rating the market has already delivered.
The institutional register is broadly stable. Vanguard holds 12.6% and BlackRock 9.5%, with FMR adding 137,000 shares in the most recent filing period — a modest but directionally positive move from a top-three holder. Insider activity through late February consisted of small, low-significance sales by senior vice presidents and legal officers at prices around $246, well above current levels. Those trades carry a significance score of 1 — routine rather than informative.
Today's print will test whether the Omnipod 5 international rollout and new customer growth are running hot enough to justify a recovery from the lows, or whether the drug delivery revenue decline and competitive pressures have permanently reset expectations for what this growth rate is worth.
See the live data behind this article on ORTEX.
Open PODD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
